4536 — Santen Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual cashflow statement for Santen Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	—	—	—	IFRS	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	27,189	-14,983	26,703	35,853	37,561
Depreciation
Non-Cash Items	8,253	47,577	15,743	12,199	7,305
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-6,454	-12,696	12,025	-5,072	-19,724
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	46,043	37,147	72,649	60,928	43,500
Capital Expenditures	-35,841	-24,588	-10,687	-11,019	-14,266
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	672	-2,189	4,542	2,796	1,292
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-35,169	-26,777	-6,145	-8,223	-12,974
Financing Cash Flow Items	147	445	217	0	-601
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	5,557	-37,220	-34,031	-53,307	-49,348
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	20,125	-25,111	36,679	-1,585	-12,122